Connect with us

Health

Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business

Published

on

Article feature image

Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Emerging SARS-CoV-2 variants contain mutations that interfere with genomic sequencing – News-Medical.Net
Article feature image
Delta strain doubles hospitalisation risk – The West Australian